NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on non-antibiotic anti-infectives, announced today that CEOLIVE.TV, an online service that delivers news about companies to investors, has highlighted NovaBay’s important advance in eye care through an interview with Kathryn Najafi-Tagol, M.D., the founder and director of the Eye Institute of Marin in San Rafael, California.
In the interview with Mike Elliott of CEOLIVE.TV, Dr. Najafi-Tagol described the success she’s been having with NovaBay’s new i-Lid™ Cleanser:
“The product came out of the frustration I was having with treating a very common eye condition called blepharitis,” said Dr. Najafi-Tagol. “More than half of the patients who come in for the treatment of glaucoma, cataract, or macular degeneration also have blepharitis or meibomian gland dysfunction,” she explains. Blepharitis is typically caused by the growth of staphylcocci bacteria on eyelids, causing swelling, redness, inflammation, irritation, and a crusty build-up. The bacteria can also produce toxins that break down secretions from the meibomian gland, leading to meibomian gland dysfunction and dry eye syndrome. “These are all very serious conditions,” she said.
For years, physicians have been treating these patients with existing eyelid hygiene products such as wipes, antibiotics, and steroids. However, many patients develop chronic inflammation and damage to their eyelids and glands despite treatment. Some patients suffer from blepharitis chronically for many years. Moreover, many traditional treatments have caused concern about creating antibiotic-resistant bacteria or increasing pressure in the eye. “Doctors needed something better,” Dr. Najafi-Tagol said.
So she turned to i-Lid Cleanser, which she helped develop as an advisor to NovaBay. It is a stable pure form of hypochlorous solution (HOCl) in saline, a substance naturally made by the body’s immune system as a first defense against microbial invaders. Laboratory tests show that i-Lid Cleanser not only kills bacteria, it also neutralizes the toxins produced by bacteria—and is safe as a skin cleanser.
Dr. Najafi-Tagol now uses i-Lid Cleanser extensively in her practice as part of the treatment of blepharitis, and to clean eyes of any debris and crusting for 5 days before cataract or glaucoma surgery. For her patients, i-Lid Cleanser has brought major improvements in their quality of life, as described by several patients in this video.
Dr. Najafi-Tagol isn’t alone in her opinion of i-Lid Cleanser. Professor Christine W. Sindt O.D., Optometrist and Clinical Associate Professor of Ophthalmology and Visual Sciences at the University of Iowa, describes i-Lid Cleanser as the “21st Century lid and lash hygiene product” in a May issue of RCCL (Review of Cornea and Contact Lenses page 7). “Baby shampoos as well as some eyelid cleansers contain chemicals such as cocamidopropyl betaine, a surfactant and lathering agent that may cause eyelid dermatitis,” says Prof. Sindt.
Because so many patients suffer from these eye conditions, Dr. Najafi-Tagol believes the potential market for i-Lid Cleanser is “huge.”
This release contains forward-looking statements and opinions, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs, and also those of unaffiliated individuals. These statements include, but are not limited to, statements regarding the general effectiveness of NovaBay’s products, potential market size for NovaBay products, and the quoted opinions of NovaBay products by certain physicians. The words “believes,” “show,” and “can” are intended to identify these forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the actual effectiveness of NovaBay products and unexpected adverse side effects or inadequate therapeutic efficacy of i-Lid Cleanser. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson